1
|
Liu Z, Zhao J, Wang Y, Luo H. Comparative study on registration application of proprietary Chinese medicine in the Guangdong-Hong Kong-Macau Greater Bay Area of China. J Pharm Policy Pract 2024; 17:2325516. [PMID: 38628567 PMCID: PMC11020596 DOI: 10.1080/20523211.2024.2325516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2024] Open
Abstract
Background Proprietary Chinese medicine (PCM) is widely used in the Guangdong-Hong Kong-Macau Greater Bay Area (GBA) of China. However, the regulatory frameworks and procedures for PCM registration in the region are not well-established, and there are differences among the three jurisdictions. The study is aimed to compare the legal basis, regulatory guidelines, application requirements, and evaluation criteria in each jurisdiction. Methods We conducted a comprehensive review of the registration application processes for PCMs in the Chinese mainland, Hong Kong, and Macau based on publicly available information from respective regulators. Results The study found that the registration application process in the GBA was complex and time-consuming, with differences in requirements and procedures among the three jurisdictions. The study also identified several challenges faced by PCM manufacturers, such as the lack of harmonisation of regulatory requirements and procedures and the requirement of package inserts and labelling for PCM products. The study proposed recommendations for improving the registration process and promoting the development of the PCM industry in the GBA. Conclusion This study provides a comprehensive understanding of the PCM product license application procedures and requirements in the GBA, coupled with discernment of their similarities and disparities, equips applicants with the knowledge to formulate an appropriate strategy for obtaining product approval. Exploring potential methods for harmonising the regulatory process stands to benefit manufacturers, regulators, and patients by improving efficiency and curtailing costs.
Collapse
Affiliation(s)
- Zicheng Liu
- Macau Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, People’s Republic of China
| | - Jinmin Zhao
- College of Pharmacy, Guangxi Medical University, Nanning, People’s Republic of China
| | - Yitao Wang
- Macau Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, People’s Republic of China
| | - Hua Luo
- Macau Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, People’s Republic of China
- College of Pharmacy, Guangxi Medical University, Nanning, People’s Republic of China
| |
Collapse
|
2
|
Chen L, Wei S, He Y, Wang X, He T, Zhang A, Jing M, Li H, Wang R, Zhao Y. Treatment of Chronic Gastritis with Traditional Chinese Medicine: Pharmacological Activities and Mechanisms. Pharmaceuticals (Basel) 2023; 16:1308. [PMID: 37765116 PMCID: PMC10537303 DOI: 10.3390/ph16091308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 08/14/2023] [Accepted: 08/18/2023] [Indexed: 09/29/2023] Open
Abstract
Chronic gastritis (CG) is a common clinical digestive system disease, which is not easyily cured and is prone to recurrence. Traditional Chinese medicine (TCM) plays a significant role in the treatment of CG and has attracted increasing attention for clinical applications. In recent years, a large number of reports have shown that TCM has good therapeutic effect on CG. The aim of this paper is to investigate the pharmacological activities and mechanism of action of TCM in the treatment of CAG. Therefore, by searching the databases of Pubmed, China National Knowledge Infrastructure, Wanfang, and Baidu academic databases, this paper has summarized the molecular mechanisms of TCM in improving CG. The results show that the improvement of GC by TCM is closely related to a variety of molecular mechanisms, including the inhibition of Helicobacter pylori (Hp) infection, alleviation of oxidative stress, improvement of gastric function, repair of gastric mucosa, inhibition of inflammatory response, and apoptosis. More importantly, IRF8-IFN-γ, IL-4-STAT6, Hedgehog, pERK1/2, MAPK, PI3K-Akt, NF-κB, TNFR-c-Src-ERK1/2-c-Fos, Nrf2/HO-1, and HIF-1α/VEGF signaling pathways are considered as important molecular targets for TCM in the treatment of GC. These important findings will provide a direction and a basis for further exploring the pathogenesis of GC and tapping the potential of TCM in clinical treatment. This review also puts forward a bright prospect for future research of TCM in the treatment of CG.
Collapse
Affiliation(s)
- Lisheng Chen
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
- Department of Pharmacy, General Hospital of PLA, Beijing 100039, China
| | - Shizhang Wei
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
| | - Yong He
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
| | - Xin Wang
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
| | - Tingting He
- Division of Integrative Medicine, The Fifth Medical Center, General Hospital of PLA, Beijing 100039, China; (T.H.); (A.Z.); (R.W.)
| | - Aozhe Zhang
- Division of Integrative Medicine, The Fifth Medical Center, General Hospital of PLA, Beijing 100039, China; (T.H.); (A.Z.); (R.W.)
| | - Manyi Jing
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
| | - Haotian Li
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
| | - Ruilin Wang
- Division of Integrative Medicine, The Fifth Medical Center, General Hospital of PLA, Beijing 100039, China; (T.H.); (A.Z.); (R.W.)
| | - Yanling Zhao
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; (L.C.); (Y.H.); (X.W.); (M.J.); (H.L.)
- Department of Pharmacy, General Hospital of PLA, Beijing 100039, China
| |
Collapse
|
3
|
Xie MJ, Tu PF, Zhang QY. [Research advances of Zaoren Anshen prescription preparations]. Zhongguo Zhong Yao Za Zhi 2021; 46:1301-1326. [PMID: 33787126 DOI: 10.19540/j.cnki.cjcmm.20201228.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Zaoren Anshen prescription preparations(ZRASs), which are prepared from three traditional Chinese herb medicines, namely fried Zizyphi Spinosae Semen, Salvia Miltiorrhizae Radix et Rhizoma and vinegar-processed Schisandrae Chinensis Fructus, are a series of proprietary Chinese medicines for the treatment of insomnia, amnesia and dizzy in clinic. In recent years, pharmacodynamic effect, chemical constituents and quality control of ZRASs had been extensively studied for the purpose of ensuring their safety, efficacy and stability, and a great progress had been made. However, there is no review of the research advance of ZRASs up to date. The present review summarized the research advance of ZRASs in quality control standards, chemical constituents, pharmacodynamic effects, and chemical analysis for the first time, with the aim to provide a reference for further studies on the effective constituents and quality control of ZRASs.
Collapse
Affiliation(s)
- Man-Jiang Xie
- State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines,School of Pharmaceutical Sciences,Health Science Center,Peking University Beijing 100191,China
| | - Peng-Fei Tu
- State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines,School of Pharmaceutical Sciences,Health Science Center,Peking University Beijing 100191,China
| | - Qing-Ying Zhang
- State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines,School of Pharmaceutical Sciences,Health Science Center,Peking University Beijing 100191,China
| |
Collapse
|
4
|
Zhong LLD, Lam WC, Lu F, Tang XD, Lyu A, Bian Z, Boon H. A Comparative Study for License Application Regulations on Proprietary Chinese Medicines in Hong Kong and Canada. Front Med (Lausanne) 2021; 8:617625. [PMID: 33768103 PMCID: PMC7985161 DOI: 10.3389/fmed.2021.617625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/03/2021] [Indexed: 11/13/2022] Open
Abstract
Ethnopharmacological Relevance: Chinese Medicine plays a symbolic role among traditional medicines. As Chinese Medicine products are widely used around the globe, regulations for Chinese Medicine products are often used as models for the efficient regulation of natural products that are safe, and high-quality. Aim of the Study: We aimed to compare the regulatory registration requirements for Proprietary Chinese Medicines in Hong Kong and Canada. Materials and Methods: We compared registration requirements for Proprietary Chinese Medicine in Hong Kong and Canada based on publicly available information provided by the respective Regulators. A marketed product, Zhizhu Kuanzhong Capsule (SFDA approval number Z20020003; NPN approval number 80104354), was used as a case study to demonstrate the similarities and differences of the requirements in both Hong Kong and Canada. Results: There were similarities and differences between the two regulatory systems in terms of the quality, safety and efficacy requirements. Despite the superficial appearance of similar categories and groups/classes, Hong Kong requires significantly more primary test data compared to Canada's reliance on attestation to manufacturing according the standards outlined in approved reference pharmacopeias/texts. Conclusion: Improved understand of the similarity and differences will enable applicants to plan appropriate strategies for gaining product approval. Exploring ways to harmonize the regulatory process has the potential to benefit manufacturers, regulators, and patients by increasing efficiency and decreasing costs.
Collapse
Affiliation(s)
- Linda L D Zhong
- Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, Hong Kong, China.,School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.,Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
| | - Wai Ching Lam
- Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, Hong Kong, China.,School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.,Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States
| | - Fang Lu
- China Academy of Chinese Medical Sciences, Beijing, China
| | - Xu Dong Tang
- China Academy of Chinese Medical Sciences, Beijing, China
| | - Aiping Lyu
- Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, Hong Kong, China.,School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | - Zhaoxiang Bian
- Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, Hong Kong, China.,School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | - Heather Boon
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
| |
Collapse
|